Does elevated fecal sIgA with a high stool inflammation score indicate mucosal surface immune activation?

Evaluating gastrointestinal health requires a clear differentiation between localized mucosal surface immune responses and invasive, tissue-damaging inflammatory pathology.

Clinical differentiation

• Ruling out invasive inflammation: Fecal calprotectin and lactoferrin are highly concentrated within neutrophils, the primary cellular drivers of invasive intestinal inflammation. Normal calprotectin, negative lactoferrin, and the absence of stool white blood cells (WBCs) strongly rule out neutrophil-dominant, invasive tissue injury.
• Identifying mucosal activation: An elevated fecal secretory IgA (sIgA) combined with an elevated stool inflammation score indicates localized mucosal surface immune activation. This distinct, discordant biomarker pattern demonstrates active mucosal defense in the absence of active neutrophilic infiltration or structural tissue damage.

Mechanistic explanations

• Adaptive barrier defense: Fecal sIgA serves as the primary antibody-based defense at mucosal surfaces. Its elevation represents adaptive mucosal immunity and localized immune exclusion, helping to neutralize microbes and prevent their attachment to epithelial surfaces.
• Triggers of non-invasive activation: This localized upregulation of sIgA is typically triggered by non-invasive luminal stimuli—such as dysbiosis, food antigens, or superficial infections. These stimuli activate epithelial surface defenses and barrier responses without recruiting neutrophils or causing deep, tissue-damaging inflammatory injury.

Bottom line

• An elevated fecal sIgA and stool inflammation score in the setting of normal calprotectin, negative lactoferrin, and absent stool WBCs is highly consistent with localized, non-invasive mucosal surface immune activation and rules out neutrophil-dominant invasive inflammation.